Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Keros Therapeutics's price to sales ratio was 13.0× on Nov 11, 2026, against 2.9× a year earlier. Over the last 3 years it ranged from 0.9× to 460.6×, with a median of 7.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 13.0× | +9.6 |
| 2025 | Dec 31, 2025 | 3.4× | −59.8 |
| 2022 | Apr 29, 2022 | 63.2× | −397.4 |
| 2021 | Jan 29, 2021 | 460.6× | +236.5 |
| 2020 | Oct 30, 2020 | 224.2× | – |
See a number that looks wrong?